Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Healthcare.
Press releases published on August 5, 2025
Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12
GlobeNewswire
·
August 5, 2025
DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the …
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights
GlobeNewswire
·
August 5, 2025
Three presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of metabolic health: In patients with type 2 diabetes (T2D) not achieving glycemic targets, icovamenib demonstrated durable HbA1c reduction and …
Amwell® Announces Results for Second Quarter 2025
GlobeNewswire
·
August 5, 2025
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended June 30. The company’s second quarter …
Ceribell Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 5, 2025
SUNNYVALE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial …
Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
August 5, 2025
Phase 1 trial of TERN-701 in chronic myeloid leukemia (CML) enrolling well; efficacy and safety data including 6-month major molecular response (MMR) rates expected in 4Q25 Phase 2 trial of TERN-601 for obesity completed enrollment; 12-week efficacy, …
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
GlobeNewswire
·
August 5, 2025
Highlights Second quarter 2025 revenue of $213.1 million increased by 1% year-over-year. Excluding previously discussed headwinds1 of $9.5 million, revenue increased 5% year-over-year. Second quarter 2025 hereditary cancer testing revenue and volume in …
Treace Announces Peer-Reviewed Publication of Four-Year Results of the ALIGN3D™ Lapiplasty® Multicenter Prospective Clinical Study
GlobeNewswire
·
August 5, 2025
PONTE VEDRA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, …
LifeMD Reports Second Quarter 2025 Results
GlobeNewswire
·
August 5, 2025
Total revenue increased 23% year-over-year to $62.2 million; adjusted EBITDA rose 223% to $7.1 million Telehealth revenue increased 30% to $48.6 million; telehealth adjusted EBITDA rose 560% to $3.4 million Generated more than $8 million of operating cash …
OraSure Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
August 5, 2025
BETHLEHEM, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2025 …
Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 5, 2025
SEATTLE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products …
OrthoPediatrics Corp. Reports Second Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance
GlobeNewswire
·
August 5, 2025
WARSAW, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the second …
Clover Health Reports Second Quarter 2025 Results; Delivering Strong Sustainable Growth
GlobeNewswire
·
August 5, 2025
Second quarter 2025 Medicare Advantage membership of 106,323, up 32% year-over-year Second quarter 2025 Total revenues of $478 million, up 34% year-over-year Second quarter 2025 profitability metrics with GAAP Net loss of $11 million, Adjusted EBITDA of $ …
Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure
GlobeNewswire
·
August 5, 2025
Two-year follow-up in Germany Real-World Registry study showed median 9.6% weight loss and 1.6% HbA1c reduction after a single Revita procedure in participants with type 2 diabetes, with no device- or procedure-related serious adverse events to date New …
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
GlobeNewswire
·
August 5, 2025
SCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug …
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne
GlobeNewswire
·
August 5, 2025
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne Year-over-year Q2 revenues increased by 20% to $26.6 million Adjusted EBITDA …
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 5, 2025
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to …
BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates
GlobeNewswire
·
August 5, 2025
- As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patient segment - $110.6 million in total …
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025
GlobeNewswire
·
August 5, 2025
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Generated Product Revenues of $79 million for the Three Months Ended June 30 Awarded Additional Development Funding of $27 million under the BARDA 19C Contract during the Three Months Ended June 30 Corporate …
OrthoPediatrics Corp. Announces Continued Expansion of Specialty Bracing Division Into New Territories with Multiple Clinics
GlobeNewswire
·
August 5, 2025
WARSAW, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its OrthoPediatrics …
Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update
GlobeNewswire
·
August 5, 2025
Second quarter total revenue of $166 million, Crysvita® revenue of $120 million and Dojolvi® revenue of $23 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and …